Literature DB >> 18840506

The coenzyme Q10 status of the brain regions of Parkinson's disease patients.

Iain P Hargreaves1, Amelia Lane, Patrick M A Sleiman.   

Abstract

There is increasing evidence that impairment of mitochondrial function and oxidative damage are contributing factors to the pathophysiology of Parkinson's disease (PD). Studies have reported decreased levels of the mitochondrial electron transport chain carrier, coenzyme Q(10) (CoQ(10)) in plasma and platelets from PD patients. Although a deficit in peripheral CoQ(10) has been reported no studies have assessed the CoQ(10) status of the PD brain. In this study we investigated the CoQ(10) status of the substantia nigra, cerebellum, cortex and striatum brain regions of both PD patients and age-matched controls. The results of this study indicate a significant reduction (p=0.007) in CoQ(10) concentration in the cortex region of the brain. In conclusion, the results of this study indicate evidence of a deficit in brain CoQ(10) status may be involved in the pathophysiology of PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840506     DOI: 10.1016/j.neulet.2008.09.069

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  Nutrition and Lifestyle Intervention on Mood and Neurological Disorders.

Authors:  Gary Null; Luanne Pennesi; Martin Feldman
Journal:  J Evid Based Complementary Altern Med       Date:  2016-03-14

2.  Coenzyme Q10 deficiency in patients with Parkinson's disease.

Authors:  Laurie K Mischley; Jason Allen; Ryan Bradley
Journal:  J Neurol Sci       Date:  2012-04-27       Impact factor: 3.181

Review 3.  Coenzyme Q10 and Parkinsonian Syndromes: A Systematic Review.

Authors:  Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  J Pers Med       Date:  2022-06-15

Review 4.  Coenzyme Q10 effects in neurological diseases.

Authors:  H Rauchová
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

5.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

6.  Coenzyme Q10 effects in neurodegenerative disease.

Authors:  Meredith Spindler; M Flint Beal; Claire Henchcliffe
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

7.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

8.  Knockdown of the coenzyme Q synthesis gene Smed-dlp1 affects planarian regeneration and tissue homeostasis.

Authors:  Yumiko Shiobara; Chiaki Harada; Takeshi Shiota; Kimitoshi Sakamoto; Kiyoshi Kita; Saeko Tanaka; Kenta Tabata; Kiyoteru Sekie; Yorihiro Yamamoto; Tomoyasu Sugiyama
Journal:  Redox Biol       Date:  2015-10-21       Impact factor: 11.799

9.  Coenzyme q10 abrogated the 28 days aluminium chloride induced oxidative changes in rat cerebral cortex.

Authors:  Anuradha S Majumdar; Abhijit Nirwane; Rahul Kamble
Journal:  Toxicol Int       Date:  2014-05

Review 10.  Coenzyme Q10 and Neurological Diseases.

Authors:  Michelangelo Mancuso; Daniele Orsucci; Valeria Calsolaro; Anna Choub; Gabriele Siciliano
Journal:  Pharmaceuticals (Basel)       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.